<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20131202144600Z</creation_date><modification_date>D:20170103113400Z</modification_date><initial_authorization>True</initial_authorization><pdf_file>EU-1-16-1158_h_dec_0.pdf</pdf_file></head><body><section><header>en en</header><p>european commission
 bruxelles, 4.1.2017c(2017)44 (final)</p></section><section><header>commission implementing decisionof 4.1.2017
 granting marketing authorisation under regulation (ec) no 726/2004 of the european 
 parliament and of the council for &quot;afstyla - lonoctocog alfa&quot;, a medicinal product for 
 human use</header><p>(text with eea relevance) (only the german text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decisionof 4.1.2017
 granting marketing authorisation under regulation (ec) no 726/2004 of the european 
 parliament and of the council for &quot;afstyla - lonoctocog alfa&quot;, a medicinal product 
 for human use</header><p>(text with eea relevance)(only the german text is authentic)
 the european commission,
 having regard to the treaty on the functioning of the european union,
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a european 
 medicines agency
 1, and in particular article 10(2) thereof,having regard to the application submitted by csl behring gmbh, on 31 december 2015, 
 under article 4(1) of regulation (ec) no 726/2004,
 having regard to the opinion of the european medicines agency, formulated on 10 
 november 2016 by the committee for medicinal products for human use,
 whereas:
 (1)
 the medicinal product &quot;afstyla - lonoctocog alfa&quot; complies with the requirements 
 set out in directive 2001/83/ec of the european parliament and of the council of 6 
 november 2001 on the community code relating to medicinal products for human use
 2.(2)
 it is therefore appropriate to authorise its placing on the market.
 (3)
 the committee for medicinal products for human use considered that &quot;lonoctocog 
 alfa&quot; is a new active substance.
 (4)
 the measures provided for in this decision are in accordance with the opinion of the 
 standing committee on medicinal products for human use,
 has adopted this decision:
 article 1the marketing authorisation provided for in article 3 of regulation (ec) no 726/2004 is granted for the medicinal product &quot;afstyla - lonoctocog alfa&quot;, the characteristics of which 
 1oj l 136, 30.4.2004, p. 1.2oj l 311, 28.11.2001, p. 67.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>are summarised in annex i to this decision. &quot;afstyla - lonoctocog alfa&quot; shall be registered in the community register of medicinal products under number eu/1/16/1158.
 article 2the marketing authorisation concerning the medicinal product referred to in article 1 shall be subject to compliance with the conditions set out in annex ii and, in particular, with those 
 relating to manufacture and importation, control and issue.
 article 3the labelling and package leaflet concerning the medicinal product referred to in article 1 shall comply with the conditions set out in annex iii.
 article 4the period of validity of the authorisation shall be five years from the date of notification of this decision.
 article 5this decision is addressed to csl behring gmbh, emil-von-behring-straße 76, d-35041 marburg, deutschland.
 done at brussels, 4.1.2017
 for the commissionxavier prats monné
 director-general</p></section></body></xml>